Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Filed May 13, 2020 · 10-Q · 43 days after period end · 0001564590-20-024866
| Metric | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|
| Revenue | $750.00K | — | — |
| Net Income | -$18.45M | -$36.84M | -$6.94M |
| EPS Diluted | -$0.81 | -$24.29 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
ended Mar 31, 2020 · filed May 13, 2020 · 43 d after period end
